250 results about "Sulfated polysaccharides" patented technology

Methods and compositions for treating or preventing microbial infection in mammals with sulfated polysaccharides wherein the polysaccharides have a degree of sulfation effective to enable maximal interaction of constituent sulfate groups with the microbe which causes the infection and wherein the sulfated polysaccharide is not substantially endocytosed or degraded by cell receptor binding in the mammal and thereby retains antimicrobial activity in vivo.

A method and medicament for anticoagulating a patient with a sulfated polysaccharide mixture that demonstrates enhanced anti-inflammatory activity compared to anticoagulation with unfractionated heparin comprising various combinations of fully anticoagulant unfractionated heparin with 2-O desulfated heparin demonstrating reduced anticoagulant activity but enhanced anti-inflammatory actions. The medicament preferably is administered intravenously, by aerosolization or orally. Preferably, the 2-O desulfated heparin medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, normal saline and distilled water. Additionally provided is a method of synthesizing 2-O desulfated heparin in commercially practical quantities for the formulation of an anticoagulant 2-O desulfated heparin and heparin mixture.

Heterogeneous intimate admixtures of sulfated heparinic polysaccharides, well suited for the prophylaxis / treatment of acute thrombotic episodes in a human patient, comprise immixture of sulfated polysaccharides having a weight average molecular weight less than that of heparin and which include from 9% to 20% of polysaccharide chains having a molecular weight less than 2,000 daltons and from 5% to 20% of polysaccharide chains having a molecular weight greater than 8,000 daltons, the ratio between the weight average molecular weight and the number average molecular weight thereof ranging from 1.3 to 1.6.

A method and medicament for treating inflammation in a patient with a sulfated polysaccharide without inducing platelet activation or thrombosis in the presence of heparin- and platelet factor 4-complex reactive antibodies using a 2-O desulfated heparin with an average degree of sulfation of 0.6 sulfate groups per monosaccharide or greater and an average molecular weight or 2.4 kD or greater. The medicament preferably is administered intravenously, by aerosolization or orally. Preferably, the 2-O desulfated heparin medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, normal saline, and distilled water. Additionally provided is a method of synthesizing 2-O desulfated heparin.

The invention relates to methods and products associated with analyzing and monitoring heterogeneous populations of sulfated polysaccharides. In particular therapeutic heparin products including low molecular weight heparin products and methods of analyzing and monitoring these products are described.

The present invention provides bioconjugates comprising a sulfated polysaccharide such as alginate sulfate and hyaluronan sulfate and at least one bioactive polypeptide capable of binding a sulfate group of said sulfated polysaccharide. The bioactive polypeptide can be a heparin-binding polypeptide and / or a positively-charged polypeptide. Also, provided are delivery systems and methods for sustained release of said bioactive polypeptide(s) using said bioconjugates.

The invention relates to a method for preparing low molecular weight brown seaweed fucoidan sulfate. The method comprises a step of oxidatively degrading brown seaweed sulfated polysaccharides by hydroxyl radical and a step of ultrafiltration membrane separation and purification, wherein raw sugar of the brown seaweed sulfated polysaccharide is used as a raw material, the hydroxyl radical generated by the reaction of copper ions and hydrogen peroxide is adopted to oxidatively degrade the raw sugar of the brown seaweed sulfated polysaccharide, and the membrane separation technology is combined in the method for preparing the low molecular weight fucoidan sulfate from the brown seaweeds. In the preparation process, the oxidizing speed is uniform, the reacting condition is mild, and the controllability and repeatability are good; the copper ions are removed by a chelating column after the oxidation reaction is finished, so the operation process is simple. Furthermore, the pH value is adjusted by adding little acid and alkali, so the salt content in the product is low, and can be completely removed by a 300Da ultrafiltration membrane in the ultrafiltration membrane separation and purification process. The ultrafiltration membrane can effectively separate and purify the brown seaweed fucoidan with different molecular weights along with high separating speed and large treatment amount. The method is suitable for industrial production.

A method and medicament for treating and preventing platelet activation or thrombosis in the presence of heparin-and platelet factor 4-complex reactive antibodies using a 2-O desulfated heparin with an average degree of sulfation of 0.6 sulfate groups per monosaccharide or greater and an average molecular weight or 2.4 kD or greater. The medicament preferably is administered intravenously, by aerosolization or orally. Preferably, the 2-O desulfated heparin medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, normal saline, and distilled water. Additionally provided is a method of synthesizing 2-O desulfated heparin.

Methods and compositions for treating or preventing acute or chronic viral infection over a short time interval in mammals with sulfated polysaccharides wherein the polysaccharides have a percent of sulfur with respect to the sugar residue effective to enable maximal interaction of constituent sulfate groups with the microbe which causes the infection and wherein the sulfated polysaccharide is not substantially endocytosed or degraded by cell receptor binding in the mammal and thereby retains antiviral activity in vivo.

Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having blood coagulation enhancing activity. Compositions and kits for practicing methods of the invention are also described.

The invention relates to a preparation method of sulfated polysaccharide. Firstly, the polysaccharide reacts with organic silicon and then reacts with sulfuric acid esterification reagent such as sulfur trioxide-pyridine complex, chlorosulfonic acid and the like, and finally the sulfated polysaccharide is prepared. The method has the advantages of mild reaction, easy control, high yield and good repeatability. By utilizing the method, sulfated polysaccharide with wider scope of sulfated degree can be prepared, the sulfated substitution degree can be up to 2.95 at most, moreover, the polysaccharide degradation in the reaction process is less, the side effects are less, the product color is light, and the product is especially suitable for being applied as a drug.

Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.

A method of factor XI-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject. A method of factor XI-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising: (i) selecting a subject that is not deficient for factor XI; and (ii) administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject, wherein the NASP enhances blood coagulation in a factor XI-dependent manner. A method of identifying a non-anticoagulant sulfated polysaccharide (NASP) which is capable of enhancing blood coagulation in dependence on FXI, the method comprising: a) combining a blood or plasma sample comprising activation competent FXI with a composition comprising a sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample; b) combining a corresponding blood or plasma sample deficient in activation competent FXI with a composition comprising the sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample; and c) comparing the clotting or thrombin generation parameters of the blood or plasma samples as determined in steps (a) and (b) with each other, wherein a decrease in the clotting time of the blood sample or an increase in peak thrombin or decrease in peak time of the plasma sample comprising activation competent FXI compared to the clotting time of the blood sample or peak thrombin or peak time of the plasma sample deficient in activation competent FXI is indicative of a NASP which is capable of enhancing blood coagulation in dependence on FXI.

The present invention relates to the field of nutraceuticals, and in particular to nutraceuticals comprising sulfated polysaccharides, Astragalus polysaccharides, resveratrol, and combinations thereof. These compositions find use in inducing physiological responses such, decreasing body fat, increasing lean body mass, alleviating the symptoms of colds, preventing the onset of colds, increasing energy, increasing the feeling of well-being in subjects, and improving skin tone and appearance.

The invention discloses a novel application of fucoidan sulfate in prevention and cure of a parkinson disease. According to the experiments of an isolated PD cell model and an in vivo animal model, fucoidan sulfate has a certain neuroprotection effect on DA cholinergic neurons of the PD cell model and animal model and can prevent and cure the PD disease. The fucoidan sulfate of the invention can be natural polysaccharide extracts obtained form brown alga such as kelp, focus, bladder wrack, sea-tangle or chorda filum and also can be materials such as low molecular weight SSPSA or oligosaccharide which are obtained through the degradation of fucoidan sulfate.

A polyguluronic acid ester having a chemical name of L-polyguluronic aldonic acid-2, 3-sulfuric acid, is prepared through the steps of first obtaining L-polyguluronic aldonic acid through acid degradation and pH grading of alginic acid, proceeding secondary acid degradation and pH grading, carrying out ultrafiltration, deposition, dewatering and drying, using sulfating agent to subject the polyguluronic acid ester to sulfation, alcohol deposition, scouring, alkaline treatment, filtering, drying and disintegrating. The polyguluronic acid ester according to the invention has strong negative ion concentration property, it can be utilized in the preparation of medicament for treating or preventing urinary lithiasis.

The present invention relates to a sulfated polysaccharide compound and the preparation and use thereof, and in particular to a narrow distribution low molecular weight, highly sulfated pentosan (in this instance a xylan) referred to as glucuronoxylan sulfate (GXS). The invention has been developed primarily for use in the treatment of various clinical conditions. However, it will be appreciated that the invention is not restricted this particular field of use.

In a process for preparing Tissue Factor Pathway Inhibitor (TFPI) by the genetically engineered technique by the use of a transformed animal cell wherein a DNA encoding human TFPI is introduced, the improvement which comprises culturing said transformed animal cell in a culture medium supplemented with a sulfated polysaccharide to protect an intact TFPI produced by said transformed animal cell from cleavage by proteases present in the culture medium.

The invention discloses a process for producing concentrated and purified heparin, which comprises the following steps of: separating, concentrating and purifying heparin, impure protein, nucleic acid and rest sulfated polysaccharide at one time in solution of a coarse heparin product by using expansion column bed technology. The process changes the traditional process finished by multiple steps of a salt hydrolysis-ion exchange resin method. Fine heparin is separated, concentrated and purified by adopting the expansion column bed and ion exchange resin process, sedimentation is performed by adopting ethanol, dehydration is performed by adopting acetone, and the potency of the heparin is more than 180IU / mg. The expansion column bed and ion exchange resin process reduces the working procedure, shortens the time, lowers the cost, and improves the efficiency and quality.

The invention discloses a method for purifying dermatan sulfate from a heparin byproduct. The method comprises the following steps of: using the heparin byproduct as a raw material; dissolving the heparin byproduct, and then adding potassium acetate into the dissolved heparin byproduct; adjusting the pH value of solution by using acetic acid to generate a deposit, wherein clear solution is sulfate polysaccharide solution; adding a Ban's agent and saturated sodium hydroxide solution into the sulfate polysaccharide solution; centrifugally collecting the deposit; performing re-precipitation; dissolving the deposit again; washing away copper ions by using a chromatography column with anion exchange properties and sodium chloride solution; performing linear gradient elution by using the sodium chloride solution; collecting eluant; and evaporating and concentrating the eluant, and depositing the eluant by using ethanol to obtain high-purity dermatan sulfate. The method has the advantages of simple purification process, high purification yield, low cost, easy amplification and suitability for industrial production.

The invention provides low-molecular-weight fucosylated chondroitin sulfate, a preparation method thereof and application of the low-molecular-weight fucosylated chondroitin sulfate to the preparation of medicine for resisting Trousseau syndrome. Sulfated polysaccharide with the main chain using beta-1,4-D-glucuronic acid and beta-1,3-D-acetamino galactose as disaccharide repeating units and the branch chain being alpha-1,3-L-fucus oligosaccharide sulfate. Experiments show that the fucosylated chondroitin sulfate has an evident inhibiting effect on the Trousseau syndrome. The fucosylated chondroitin sulfate is rich in raw material source, simple in preparation process, easy in industrialization, high in product safety, good in stability, unique in activity, promising in technical prospect in the development of medicine for resisting the Trousseau syndrome, and the like.

The present invention provides for the use of iota- and / or kappa-carrageenan for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus, paramyxovirus, adenovirus and coronavirus. The present invention further provides for the use of fucoidan, in particular of high molecular weight fucoidan, for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus and paramyxovirus.

Oral care composition comprises a stannous ion source and a thickener comprising at least 2 agents selected from the group consisting of: i) a linear sulfated polysaccharide; ii) a natural gum; iii) and a non-ionic cellulose derivative. A method for treating the oral cavity comprises administering to the oral cavity the oral care composition.

Heparin is synthesized from a polysaccharide comprised of a 1-4 glycosidically linked alternating polymer of uronic acid and glucosamine residues, wherein the uronic acid is selected from iduronic and glucuronic acid, wherein the glucosamine is partially N-sulfated; by a series of selective reactions catalyzed by recombinant enzymes.

Disclosed are methods and compositions for the treatment of a variety of disorders in subjects by affecting the glycocalyx of a subject in need of such treatment. The methods comprise administering to a subject an effective amount of a sulfated polysaccharide (SP) or analogue thereof, the SP being a non-animal based (e.g., plant, or bacteria derived) sulfated polysaccharide. The SPs can be administered as single agents, or in combination with one another, or with other medications to promote efficacy. Pharmaceutical compositions and comestibles including such SPs are also described.

The invention relates to a high-pressure water vapor degradation method for marine sulfated polysaccharides. The method is characterized in that the marine sulfated polysaccharides are prepared into water solution, then the water solution is treated by high-pressure water vapor at the temperature of 101-150 DEG C for 0.01-24hours, and the obtained treatment solution is dried for obtaining degraded products of the polysaccharides. The marine sulfated polysaccharides comprise seaweed fucoidan, carrageenan and agaropectin which are sourced from marine plants, as well as sea cucumber chondroitin sulfate, sea cucumber fucoidan and abalone sulfated polysaccharides, which are sourced from marine animals. The method has the advantages that no inorganic salt is introduced, and the final products can be obtained by drying after degradation without desalinization; the molecular weight of the polysaccharides can be reduced continuously and uniformly, and the degraded products with different molecular weight can be obtained by controlling the treatment conditions and the treatment time; the method is stable, and the reproducibility is good; and the requirement on equipment is low, and the operation is simple.

Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) in combination with a gastrointestinal epithelial barrier permeation enhancer is orally administered to a subject in a manner sufficient to enhance blood coagulation in the subject. Compositions and kits for practicing methods of the invention are also described.

A method and medicament is provided for treating and inhibiting interaction of the receptor for advanced glycation end-products (RAGE) and its ligands using a natural or synthetic sulfated polysaccharide, preferably a 2-O desulfated heparin. The medicament preferably is administered intravenously, by aerosolization, intra-nasally, intra-articularly, intra-thecally, subcutaneously, topically or orally. The medicament is useful for treating a variety of conditions, including diabetes, inflammation, renal failure, aging, systemic amyloidosis, Alzheimer's disease, inflammatory arthritis, atherosclerosis, and colitis.

This invention relates to methods for treating, preventing or managing coronavirus infections in mammals using sulfated polysaccharides. More particularly, this invention relates to methods of treating, preventing or managing infection by coronaviruses, particularly viral infections leading to or causing diseases such as the newly discovered Severe Acute Respiratory Syndrome (“SARS”). The invention involves the use of sulfated polysaccharides which are abundant, non-toxic and inexpensive and which are potent antivirals in vivo.

The invention discloses a fucoidan-galactosan sulfate with a novel structure. Fucoidan-galactosan sulfate provided by the present invention is a sulfated polysaccharide composed of fucose and galactose. According to the chemical constitution of the sugar chain, a fundamental chain is formed by -4-alpha-L-Fuc-(1,3)-alpha-L-Fuc-(1,3)-alpha-L-Fuc-(1,3)-alpha-L-Fuc-(1-residue. Every 4 sugar residues comprise a branched chain, which is composed of alpha-L-Fuc(1- or beta-D-Gla-(1,6)-beta-D-Gla-(1-. Sulfated group is connected to the 2 or 4 site of fucose, or on the 3 or 4 site of galactose. Meanwhile, the invention discloses a preparation method and an application of fucoidan-galactosan sulfate. Fucoidan-galactosan sulfate provided by the present invention can be exploited into medicines for treating kidney diseases.